PSNL Personalis
- 3.690
- +0.100+2.79%
- 3.690
- 0.0000.00%
Personalis News
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Maintains Target Price $5
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Raises Target Price to $5
Personalis: Promising Growth in Biopharma Sales Amidst Strategic Challenges – Hold Rating Maintained
A Quick Look at Today's Ratings for Personalis(PSNL.US), With a Forecast Between $7 to $9
H.C. Wainwright Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $9
Needham Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $7.25
Personalis Analyst Ratings
Needham Reiterates Buy on Personalis, Maintains $7.25 Price Target
Personalis: Strong Revenue Growth and Strategic Advances Justify Buy Rating
TD Cowen Maintains Personalis(PSNL.US) With Buy Rating
TD Cowen Remains a Buy on Personalis (PSNL)
Lake Street Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $8
Lake Street Keeps Their Buy Rating on Personalis (PSNL)
Personalis (PSNL) Receives a Buy From BTIG
BTIG Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $7
Lake Street Maintains Personalis(PSNL.US) With Buy Rating, Raises Target Price to $8
TD Cowen Maintains Personalis(PSNL.US) With Buy Rating
H.C. Wainwright Maintains Personalis(PSNL.US) With Buy Rating, Raises Target Price to $9
Personalis Price Target Raised to $7.00/Share From $5.50 by BTIG
BTIG Maintains Personalis(PSNL.US) With Buy Rating, Raises Target Price to $7
Analysis
Price Target
No Data
No Data